JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Pfizer (NYSE:PFE) Stock

Pfizer (NYSE:PFE) had its price target increased by analysts at JPMorgan Chase & Co. from $28.00 to $30.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 6.15% from the stock’s current price.

Several other research firms also recently commented on PFE. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Sunday, September 13th. BMO Capital Markets dropped their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Scotiabank boosted their target price on Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Bank of America lowered their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Five investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and a consensus price target of $28.72.

Pfizer Stock Up 1.6%

Shares of PFE traded up $0.44 during mid-day trading on Friday, hitting $28.26. 16,169,450 shares of the company’s stock were exchanged, compared to its average volume of 40,429,355. The company has a market cap of $161.08 billion, a price-to-earnings ratio of 37.17, a P/E/G ratio of 1.88 and a beta of 0.32. Pfizer has a fifty-two week low of $23.62 and a fifty-two week high of $29.21. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The stock’s 50-day moving average is $27.62 and its 200-day moving average is $26.49.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts anticipate that Pfizer will post 2.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pfizer

Several institutional investors and hedge funds have recently modified their holdings of PFE. Riversedge Advisors LLC grew its stake in Pfizer by 153.1% in the 3rd quarter. Riversedge Advisors LLC now owns 28,400 shares of the biopharmaceutical company’s stock worth $810,000 after acquiring an additional 17,180 shares during the period. Wedmont Private Capital raised its holdings in Pfizer by 138.1% in the 3rd quarter. Wedmont Private Capital now owns 99,498 shares of the biopharmaceutical company’s stock valued at $2,768,000 after acquiring an additional 57,713 shares during the last quarter. Werlinich Asset Management LLC lifted its stake in shares of Pfizer by 0.4% during the 3rd quarter. Werlinich Asset Management LLC now owns 92,600 shares of the biopharmaceutical company’s stock worth $2,641,000 after purchasing an additional 400 shares during the period. Journey Retirement Planning & Investment Management LLC acquired a new stake in shares of Pfizer during the third quarter worth $222,000. Finally, WoodTrust Financial Corp boosted its holdings in shares of Pfizer by 0.3% during the third quarter. WoodTrust Financial Corp now owns 418,180 shares of the biopharmaceutical company’s stock worth $11,927,000 after purchasing an additional 1,294 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA (tucatinib) combination with trastuzumab and pertuzumab as a chemotherapy-free frontline maintenance treatment for patients with HER2-positive metastatic breast cancer. The expanded label moves TUKYSA into an earlier stage of care, potentially broadening its addressable market and supporting Pfizer’s oncology-growth strategy. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Jefferies initiated or reiterated a Buy rating on Pfizer, while Cantor Fitzgerald raised its price target to $28, providing additional support for the stock’s valuation narrative. A separate analysis also upgraded Pfizer to a cautious bullish view. Pfizer Receives a Buy from Jefferies
• Positive Sentiment: Investors continue to view Pfizer as a potential value play because of its low forward earnings multiple, substantial cash-generation capacity and dividend yield. The company’s oncology pipeline, including TUKYSA and the advancing Phase 3 tilrekimig asthma program, may help offset pressure from slower legacy-product growth. Pfizer’s Tilrekimig Phase 3 Trial
• Neutral Sentiment: Pfizer’s next earnings report is a key catalyst. Analysts expect oncology sales, biosimilars, pipeline progress and the company’s ability to deliver another earnings beat to determine whether the valuation discount is justified.
• Negative Sentiment: Pfizer’s dividend yield above 6% is drawing scrutiny because it may reflect a depressed share price and investor concerns about earnings, cash flow, debt and payout sustainability. Commentators warn that a frozen dividend and prior write-downs make the high yield less reassuring than it appears. Pfizer’s Dividend Yield Is Above 6%
• Negative Sentiment: Pfizer plans to close a penicillin unit in Italy and eliminate approximately 330 jobs. The restructuring could improve efficiency, but it also highlights ongoing pressure to reduce costs amid sluggish revenue growth, thin margins and concerns about returns on equity.

Pfizer Company Profile

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.